Endocrine abnormality in paraneoplastic syndrome

Best Pract Res Clin Endocrinol Metab. 2022 May;36(3):101621. doi: 10.1016/j.beem.2022.101621. Epub 2022 Feb 4.

Abstract

Paraneoplastic syndromes denote rare but notable phenomena caused by the tumour mediated release of bioactive substances. Peptide and non-peptide hormone causes are explored with a particular focus on pathogenesis, symptoms, diagnosis and treatment. Early detection and management of paraneoplastic syndromes can improve morbidly and mortality; definitive treatment remains effective surgical or anti-tumour therapies. Pituitary autoimmunity may provide a novel presentation of paraneoplastic syndromes for which further research is warranted.

Keywords: cytokines; endocrine; hormones; paraneoplastic syndrome; peptides; pituitary autoimmunity.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Endocrine System Diseases* / complications
  • Endocrine System Diseases* / diagnosis
  • Humans
  • Neoplasms*
  • Paraneoplastic Endocrine Syndromes* / diagnosis
  • Paraneoplastic Endocrine Syndromes* / etiology
  • Paraneoplastic Endocrine Syndromes* / therapy
  • Paraneoplastic Syndromes* / complications
  • Paraneoplastic Syndromes* / etiology
  • Pituitary Diseases* / complications